# Regeneron Pharmaceuticals, Inc. (REGN) stock price

URL: https://funkfolio.com/stock/REGN

> Regeneron Pharmaceuticals, Inc. (REGN) is worth $99.08B and is priced at 21.2× earnings. Valuation, financials and signals.

---

## Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company (biotechnology) based in the United States. Figures as of 17 Nov 2026, 22:37 UTC, from Yahoo Finance.

### Key facts

- **Market value:** $99.08B
- **P/E ratio:** 21.2× last 12 months
- **Forward P/E:** 13.5×
- **Dividend yield:** 0.39%
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 22:37 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Regeneron Pharmaceuticals, Inc. in more detail

REGN trades at 21.2× its last twelve months' earnings, 13.5× next year's expected earnings, 5.9× sales.

10 of the superinvestors tracked here hold REGN, including Mason Hawkins (5.0% of the portfolio), Harry Burn (3.0% of the portfolio), Dodge & Cox team (1.9% of the portfolio).

### Superinvestors holding REGN

10 of the investors tracked here report a position in their latest 13F filing.

- [Mason Hawkins Southeastern Asset Management (Longleaf)](https://funkfolio.com/gurus/mason-hawkins) 4.95% of portfolio · $95M · added · Q2 2026
- [Harry Burn Sound Shore Management](https://funkfolio.com/gurus/harry-burn) 2.99% of portfolio · $95.7M · trimmed · Q3 2026
- [Dodge & Cox team Dodge & Cox](https://funkfolio.com/gurus/dodge-and-cox) 1.94% of portfolio · $3.6B · trimmed · Q3 2026
- [John Overdeck and David Siegel (founders) Two Sigma Investments](https://funkfolio.com/gurus/two-sigma) 0.48% of portfolio · $659.3M · added · Q3 2026
- [Josef Lakonishok LSV Asset Management](https://funkfolio.com/gurus/josef-lakonishok) 0.35% of portfolio · $186.6M · trimmed · Q3 2026
- [Jim Simons (1938–2024) Renaissance Technologies](https://funkfolio.com/gurus/jim-simons) 0.28% of portfolio · $206.4M · added · Q3 2026
- [Cliff Asness AQR Capital Management](https://funkfolio.com/gurus/cliff-asness) 0.25% of portfolio · $702.2M · trimmed · Q2 2026
- [Joel Greenblatt Gotham Asset Management](https://funkfolio.com/gurus/joel-greenblatt) 0.15% of portfolio · $65.6M · added · Q2 2026
- [Ray Dalio (founder) Bridgewater Associates](https://funkfolio.com/gurus/bridgewater) 0.13% of portfolio · $32M · added · Q2 2026
- [Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)](https://funkfolio.com/gurus/jeremy-grantham) 0.12% of portfolio · $53.9M · trimmed · Q3 2026

### Health Care companies of similar size

- [Vertex Pharmaceuticals VRTX](https://funkfolio.com/stock/VRTX)
- [Medtronic MDT](https://funkfolio.com/stock/MDT)
- [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY)
- [Stryker SYK](https://funkfolio.com/stock/SYK)
- [McKesson MCK](https://funkfolio.com/stock/MCK)
- [Sanofi SNY](https://funkfolio.com/stock/SNY)
- [Moderna MRNA](https://funkfolio.com/stock/MRNA)
- [CVS Health CVS](https://funkfolio.com/stock/CVS)
- [HCA Healthcare HCA](https://funkfolio.com/stock/HCA)
- [GSK GSK](https://funkfolio.com/stock/GSK)
- [Elevance Health ELV](https://funkfolio.com/stock/ELV)
- [Cigna Group CI](https://funkfolio.com/stock/CI)

Side by side: [REGN vs ELV (Regeneron Pharmaceuticals, Inc. vs Elevance Health)](https://funkfolio.com/compare/elv-vs-regn) [REGN vs GSK (Regeneron Pharmaceuticals, Inc. vs GSK)](https://funkfolio.com/compare/gsk-vs-regn) [REGN vs HCA (Regeneron Pharmaceuticals, Inc. vs HCA Healthcare)](https://funkfolio.com/compare/hca-vs-regn) [REGN vs CVS (Regeneron Pharmaceuticals, Inc. vs CVS Health)](https://funkfolio.com/compare/cvs-vs-regn) [REGN vs MRNA (Regeneron Pharmaceuticals, Inc. vs Moderna)](https://funkfolio.com/compare/mrna-vs-regn)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Regeneron Pharmaceuticals, Inc. (REGN): questions and answers

**What is REGN's P/E ratio?**

Regeneron Pharmaceuticals, Inc. trades at 21.2× its last twelve months' earnings and 13.5× next year's expected earnings.

**What is REGN's PEG ratio?**

Regeneron Pharmaceuticals, Inc.'s PEG ratio is 1.16 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is Regeneron Pharmaceuticals, Inc.'s market cap?**

Regeneron Pharmaceuticals, Inc. is valued at $99.08B.

**Does REGN pay a dividend?**

Yes. Regeneron Pharmaceuticals, Inc.'s dividend yield is 0.39%, or $3.76 a share a year, paying out 8% of earnings.

**Which famous investors own REGN?**

In their latest quarterly filings, Mason Hawkins (5.0% of the portfolio), Harry Burn (3.0% of the portfolio), Dodge & Cox team (1.9% of the portfolio), John Overdeck and David Siegel (founders) (0.5% of the portfolio), Josef Lakonishok (0.3% of the portfolio), Jim Simons (1938–2024) (0.3% of the portfolio) hold REGN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

**When does Regeneron Pharmaceuticals, Inc. report earnings next?**

Regeneron Pharmaceuticals, Inc.'s next earnings report is expected on January 28, 2027. The date comes from the market data feed and companies do move it.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Regeneron Pharmaceuticals, Inc. (REGN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/REGN

Underlying data: Yahoo Finance; company filings with the SEC.
